康方生物(09926.HK) 今日(23日)裂口高开8%后,初段曾升13.1%,一度晋身“红底股”高见100元创历史高后升幅收窄,最新报93.05元,升5.26%,成交18.81亿元。公司公布,旗下双特异性抗体新药依达方,联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的III期头对头临床试验,经独立数据监察委员会评估,期中分析显示强阳性结果,达到无进展生存期的主要研究终点。研究详细...
Source Link康方生物(09926.HK) 今日(23日)裂口高开8%后,初段曾升13.1%,一度晋身“红底股”高见100元创历史高后升幅收窄,最新报93.05元,升5.26%,成交18.81亿元。公司公布,旗下双特异性抗体新药依达方,联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的III期头对头临床试验,经独立数据监察委员会评估,期中分析显示强阳性结果,达到无进展生存期的主要研究终点。研究详细...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.